Conduit Pharmaceuticals Accounts Payable

Conduit Pharmaceuticals (CDT) currently reports a accounts payable of $360M as of June 2026. That compares with $300M in the prior-year period — up 18.2% year over year. Use the charts on this page to explore Conduit Pharmaceuticals's accounts payable history and peer comparisons.

Conduit Pharmaceuticals's accounts payable increased from $300M to $360M — a 18.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Conduit Pharmaceuticals reported $360M in accounts payable as of June 2026. That compares with $300M in the prior-year period — up 18.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $360M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Conduit Pharmaceuticals, and consider following CDT for alerts when major investors trade the stock.